LAS VEGAS, NV, April 4 /PRNewswire-FirstCall/ - Neuroscience Therapy Corp. announced today that Americans spend more than $24 billion on non-medicinal therapies. The Company believes this should increase its future revenues through its leading product: P-Stim(TM).
The amount of money spent on non-medicinal therapies, according to the American Pain Foundation, is estimated to be growing more than 15 percent each year. Neuroscience Therapy intends to benefit from these growing revenues with its leading product: P-Stim, a device that utilizes traditional acupuncture techniques as well as electro stimulation.
It is estimated that 8.2 million adults try acupuncture each year as it becomes increasingly accepted in Western society.
Neuroscience President Dr. Randolph A. Turpin said, “We feel that this trend of acceptance will be increased at an accelerated rate with the launch of P-Stim.”
The Company stated that it will initially target M.D. Acupuncturists to market P-Stim, an electro stimulation device that has been proven in Europe to treat many types of conditions without any known side effects.
About Neuroscience Therapy Corporation:
Neuroscience Therapy Corporation’s operations are located in Southern California. It holds the rights to a new, safe and innovative technology to relieve pain. Its product portfolio consists of two complimentary products: the P-Stim(TM) Electro Stimulation Device and the Multi-Point(TM) Stylus. These products have no known side effects, unlike many pharmaceutical pain relievers. The neurostimulation market is in its infancy and could reach several billion dollars in sales. The Company is working toward being a leader in this market. For more information about Neuroscience Therapy Corp., visit: www.neurosciencetherapy.com.
Legal Notice Regarding Forward Looking Statements
The statements in this press release that relate to the Company’s expectations with regard to the future impact on the Company’s results are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this document may also contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the Company’s actual results may differ materially from expected results.
Contact: Ray Johnson Investor Relations 1-866-639-3900
Neuroscience Therapy Corporation
CONTACT: Ray Johnson, Investor Relations, 1-866-639-3900
